Search research articles
Contact Us
Filters
Showing results (11-20 of 37) with videos related to
Page
of 4
Sort By:
Psychopharmacology Bulletin
|
January 1, 1995
Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry
D A Revicki, B R Luce
The American Journal of Managed Care
|
October 4, 1997
When is a cost-effectiveness claim valid? How much should the FDA care?
B R Luce, A L Hillman
International Journal of Technology Assessment in Health Care
|
January 1, 1995
The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the United States
B R Luce, R E Brown
Journal of Community Health
|
January 1, 1983
Assessing the cost-effectiveness of prevention
H D Banta, B R Luce
NIDA Research Monograph
|
December 1, 1977
The economic costs of smoking-induced illness
B R Luce, S O Schweitzer
Pharmacoeconomics
|
March 8, 1998
The role of government and private insurers in guiding and implementing pharmacoeconomic analyses
D A Freund, B R Luce
Social Science & Medicine (1982)
|
August 1, 1997
Managed care pharmacy, socioeconomic assessments and drug adoption decisions
A Lyles, B R Luce, A M Rentz
American Heart Journal
|
April 30, 1999
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care
A Stewart, J K Schmier, B R Luce
International Journal of Technology Assessment in Health Care
|
May 2, 2001
Introduction. Bayesian approaches to technology assessment and decision making
B R Luce, Y C Shih, K Claxton
Health Affairs (Project Hope)
|
January 1, 1996
The view from managed care pharmacy
B R Luce, C A Lyles, A M Rentz
Page
of 4
Search research articles
Search
Showing results (11-20 of 37) with videos related to
Sort By:
Page
of 4
Psychopharmacology Bulletin
|
January 1, 1995
Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry
D A Revicki, B R Luce
The American Journal of Managed Care
|
October 4, 1997
When is a cost-effectiveness claim valid? How much should the FDA care?
B R Luce, A L Hillman
International Journal of Technology Assessment in Health Care
|
January 1, 1995
The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the United States
B R Luce, R E Brown
Journal of Community Health
|
January 1, 1983
Assessing the cost-effectiveness of prevention
H D Banta, B R Luce
NIDA Research Monograph
|
December 1, 1977
The economic costs of smoking-induced illness
B R Luce, S O Schweitzer
Pharmacoeconomics
|
March 8, 1998
The role of government and private insurers in guiding and implementing pharmacoeconomic analyses
D A Freund, B R Luce
Social Science & Medicine (1982)
|
August 1, 1997
Managed care pharmacy, socioeconomic assessments and drug adoption decisions
A Lyles, B R Luce, A M Rentz
American Heart Journal
|
April 30, 1999
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care
A Stewart, J K Schmier, B R Luce
International Journal of Technology Assessment in Health Care
|
May 2, 2001
Introduction. Bayesian approaches to technology assessment and decision making
B R Luce, Y C Shih, K Claxton
Health Affairs (Project Hope)
|
January 1, 1996
The view from managed care pharmacy
B R Luce, C A Lyles, A M Rentz
Page
of 4